IMMP Investors Have Opportunity to Join Immutep Limited Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Immutep Limited ("Immutep" or "the Company") (NASDAQ: IMMP ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Immutep announced on March 13, 2026, "that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1 st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned ... Full story available on Benzinga.com